A phase I randomized, double-blind, placebo-controlled trial of triple combination of GLPG3067, GLPG2222 and GLPG2737 in healthy volunteers
Phase of Trial: Phase I
Latest Information Update: 05 Jan 2018
At a glance
- Drugs GLPG 2222 (Primary) ; GLPG 2737 (Primary) ; GLPG 3067 (Primary)
- Indications Cystic fibrosis
- Focus Adverse reactions; Pharmacokinetics
- 05 Jan 2018 New trial record
- 02 Jan 2018 According to a Galapagos NV media release, the first subject has been dosed in this trial.
- 02 Jan 2018 According to a Galapagos NV media release, topline results from this trial are expected to be presented at a future medical conference.